CD133在三阴性乳腺癌中的表达及其临床意义

Expression of CD133 in triple negative breast cancer and its clinical significance

目的研究三阴性乳腺癌组织中CD133的表达水平与患者临床病理资料的相关性,及其对患者预后的影响。方法纳入2008年1月至2012年12月嘉兴市第一医院就诊并进行手术治疗的三阴性乳腺癌患者70例,免疫组化检测组织中CD133的表达水平,将患者分为低表达组及高表达组,对临床病理变量进行单因素分析,利用Cox和Logistic回归进行多因素分析,以获得CD133表达水平与患者临床病理资料的相关性,并应用Kaplan-Meier曲线评估患者无病生存(disease-free survival,DFS)和总生存(overall survival,OS),Log-rank检验比较生存曲线差异。结果CD133表达在三阴性乳腺癌细胞膜和(或)细胞质中,阳性表达率为95.71%(67/70),其中,CD133低表达的患者有64.29%(45/70),高表达的患者有35.71%(25/70)。CD133高表达与患者年龄≤50岁(P=0.007)和肿瘤长径>2 cm(P=0.020)显著相关。肿瘤长径(P=0.035)、淋巴结受累情况(P=0.001)、Ki67水平(P=0.005)及CD133表达水平(P=0.014)均为三阴性乳腺癌患者发生复发转移事件的独立预测因素,淋巴结受累情况是其发生死亡事件的独立预测因素(P=0.008)。CD133高表达与患者不良预后密切相关,相较于CD133高表达的患者,低表达CD133的患者有更好的DFS(P=0.002)及OS(P=0.088),但OS差异无统计学意义。结论三阴性乳腺癌组织中CD133表达水平与患者年龄、肿瘤大小相关,其高表达与患者的复发转移事件及不良预后相关,CD133可作为三阴性乳腺癌患者预后预测标志物。

Objective To investigate the correlation between CD133 expression and clinicopathological features in triple negative breast cancer(TNBC)patients,and the impact of CD133 on prognosis in these patients.Methods Data of 70 patients who received surgical treatment in our center from Jan.2008 to Dec.2012 were collected.Immunohistochemistry was used to examine the expression of CD133.Patients were divided into two groups according to CD133 expression.Univariate analysis,Cox and Logistic regression multivariate analysis were used in order to investigate the correlation between CD133 expression and clinicopathological features.Kaplan-Meier curve and Log-rank analysis were used to evaluate DFS(disease-free survival)and OS(overall survival).Results CD133 was expressed in cytomembrane and cytoplasm with expression rate of 95.71%(67/70).Of which,64.29%(45/70)of patients were low CD133 expression and 35.71%(25/70)were high expression.High CD133 expression was significantly correlated with younger age(≤50)(P=0.007)and larger tumor size(>2 cm)(P=0.020).Tumor size(P=0.035),axillary status(P=0.001),Ki67(P=0.005)and CD133 expression(P=0.014)were independent predictors of recurrence and metastasis in TNBC patients.Axillary status was independent predictor of death event(P=0.008).Increased CD133 was associated with poor prognosis.Compared with high expression,patients with low CD133 expression had better DFS(P=0.002)and OS(P=0.088),while OS did not reach significant difference.Conclusion CD133 expression was correlated with age and tumor size in TNBC patients.High expression was associated with recurrence,metastasis and poor prognosis.Thus,CD133 may be a potential biomarker in predicting prognosis in TNBC.